• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
ESAB Corporation Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

50.82 +0.83 (+1.66%)
Delayed Quote Updated: 11:50 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 335,879
Open 50.26
Bid (Size) 50.76 (100)
Ask (Size) 50.88 (100)
Prev. Close 49.99
Today's Range 50.26 - 51.86
52wk Range 44.12 - 64.74
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction ↗
November 02, 2026
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline. 
Via The Motley Fool
News headline image
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More ↗
October 24, 2026
The company's gene-editing-focused platform looks promising. 
Via The Motley Fool

Performance

52-Week Range 21.5% below 52-week high
50.82
44.1252W Low 64.7452W High
1 Week 9.0% below 1-week high
48.751W Low 55.821W High

CRISPR Therapeutics AG - Common Shares (CRSP) traded between $44.12 and $64.74 over the past 52 weeks and last traded at $50.82, 21.5% below its 52-week high. Over the past week it ranged between $48.75 and $55.82.

Past 12 Months
-1.3%
-11.4%
+2.5%
-5.2%
-5.5%
-18.0%
1W -$0.65
1M -$6.52
3M +$1.25
6M -$2.76
YTD -$2.95
1Y -$11.15

CRSP was -18.0% over the past year, -5.2% over six months, -5.5% year to date, -1.3% in the last week.

12 Months vs Market
CRSP
-18.0%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.4%

Over the past 12 months CRSP returned -18.0% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.4%.

Volume & Liquidity 0.22× 3-mo avg
Today 335,879 3-mo avg 1.5M
1W
1.2M
1M
1.5M
3M
1.5M
6M
1.6M
YTD
1.7M
1Y
1.8M

CRSP most recently traded 335,879 shares against a 3-month average daily volume of 1.5M.

More News

Read More
News headline image
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. ↗
October 24, 2026
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 2030? ↗
October 18, 2026
Via The Motley Fool
News headline image
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗
October 18, 2026
Via The Motley Fool
Topics ETFs
News headline image
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗
October 09, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? ↗
September 29, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 24, 2026
Via The Motley Fool
News headline image
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗
September 20, 2026
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
September 17, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗
September 14, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 14, 2026
Via The Motley Fool
News headline image
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 11, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 11, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗
September 11, 2026
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
September 08, 2026
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
September 08, 2026
Via The Motley Fool
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
September 02, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
August 21, 2026
Via The Motley Fool
Topics ETFs Stocks
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
August 20, 2026
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
July 30, 2026
Via The Motley Fool
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
July 30, 2026
Via The Motley Fool
Topics Workforce
News headline image
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗
July 28, 2026
Via The Motley Fool
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
July 22, 2026
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
July 20, 2026
Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 50.82
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 11/03/26 11:50 AM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.01B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap